{"url":"https://newsforagent.com/news/2026-11-05/innate-pharma-cash-position-iph4502-data","markdown_url":"https://newsforagent.com/news/2026-11-05/innate-pharma-cash-position-iph4502-data.md","title":"Innate Pharma Posts €96.8 Million Cash Position for 2026","headline":"Innate Pharma Reports €96.8 Million in Cash and Sets IPH4502 Data for November 18","description":"Innate Pharma ended September 2026 with €96.8 million in cash and financial assets, funded partly by Sobi's $75 million upfront.","section":"Earnings & Results","published_at":"2026-11-05T06:42:06+00:00","modified_at":"2026-11-05T06:42:06+00:00","author":"News Desk","key_takeaways":["Innate Pharma held €96.8 million in cash, cash equivalents and financial assets as of September 30, 2026.","Phase 1 dose-escalation data for the Nectin-4 ADC IPH4502 will be presented at ENA 2026 on November 18, 2026.","First patient dosing in the Phase 3 TELLOMAK-3 trial of lacutamab is expected in the first quarter of 2027.","Chief Financial Officer Frédéric Lombard will step down on December 31, 2026."],"companies":[{"name":"Innate Pharma","is_primary":true,"profile_url":null,"website":"https://www.innate-pharma.com"},{"name":"Sobi","is_primary":false,"profile_url":"https://akta.pro/company-profiles/0002w1f/sobi","website":"https://sobi-uk.co.uk"},{"name":"AstraZeneca","is_primary":false,"profile_url":"https://akta.pro/company-profiles/000026p/astrazeneca","website":"https://www.astrazeneca.com"}],"source":{"publisher":"Business Wire","title":"Innate Pharma Reports Third Quarter 2026 Business and Financial Update","url":"https://www.businesswire.com/news/home/20261104506906/en/"},"other_sources":[],"tags":["Earnings & Results","Innate Pharma","Sobi","AstraZeneca"],"body_markdown":"Innate Pharma reported €96.8 million in cash, cash equivalents and financial assets as of September 30, 2026, alongside its financial update for the nine months ended September 30, 2026. The Marseille-based clinical-stage biotechnology company develops immunotherapies for cancer and is listed on Euronext Paris and Nasdaq. Business Wire [published](https://www.businesswire.com/news/home/20261104506906/en/) the update on November 5, 2026.\n\n## Innate Pharma's Cash and IPH4502 Timeline\n\nThe €96.8 million figure includes short-term investments of €20.6 million and non-current financial instruments of €6.0 million. It also reflects the $75 million upfront payment from the closing of the Sobi transaction and gross proceeds from a €30 million private placement of ordinary shares in August 2026. Financial liabilities stood at €16.2 million as of September 30, 2026, and revenues for the first nine months of 2026 were €3.4 million, against €2.3 million a year earlier. The company said its anticipated cash horizon runs until the end of the first quarter of 2028.\n\n\"As we approach year-end, our strengthened cash position enables us to work towards executing the next steps in advancing our strategic priorities,\" said Jonathan Dickinson, Chief Executive Officer of Innate Pharma.\n\nEnrollment in the Phase 1 dose-escalation of the IPH4502-101 study is complete, with 76 patients enrolled across multiple solid tumor types. Phase 1 dose-escalation data for IPH4502, a Nectin-4 exatecan ADC, will be presented as a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on November 18, 2026. Innate Pharma will host a hybrid event on IPH4502 the same day at 4:00 pm GMT, with in-person attendance in London and a live webcast.\n\nLacutamab is developed in collaboration with [Sobi](https://akta.pro/company-profiles/0002w1f/sobi), which reported higher-than-expected third-quarter 2026 profit and raised its full-year 2026 revenue forecast, according to Dagens industri. Innate Pharma is advancing TELLOMAK-3, the confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma, with first patient dosing expected in the first quarter of 2027. The study includes a confirmatory cohort in Sézary syndrome and a registrational cohort in Mycosis Fungoides.\n\n## Earlier Steps Toward the Lacutamab Study\n\nOn September 16, 2026, the Innate Pharma and Sobi partnership became effective after antitrust waiting periods expired, triggering the $75 million upfront payment, Stock Titan reported. The closing initiated the TELLOMAK-3 Phase 3 trial, with the first patient expected in the first quarter of 2027. On October 27, 2026, [AstraZeneca](https://akta.pro/company-profiles/000026p/astrazeneca) updated the expected readout of the PACIFIC-9 Phase 3 trial to the first half of 2027 from the second half of 2026, Stock Titan reported. The event-driven study evaluates durvalumab with monalizumab or oleclumab in unresectable Stage III NSCLC and has completed enrollment.\n\n## Innate Pharma's Next Dates\n\nInnate Pharma plans an FDA filing in the second half of 2027 for accelerated approval in Sézary syndrome based on existing Phase 2 TELLOMAK data once the confirmatory Phase 3 study is underway. Frédéric Lombard will step down as chief financial officer on December 31, 2026, and the company has begun a search for his replacement. The balance available under its April 2023 at-the-market sales agreement remained at $75 million as of September 30, 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}